EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer

Pei-Shan Wu, Miao-Hsia Lin, Jye-Chian Hsiao, Pei-Yi Lin, Szu-Hua Pan, Yu-Ju Chen

Molecular & Cellular Proteomics · 2023-09 · 22 (9) · 100624

DOI: 10.1016/j.mcpro.2023.100624 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2023-09. Verfasst von Pei-Shan Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Genome and Systems Biology Degree Program, National Taiwan University, Taipei, Taiwan; Institute of Chemistry, Academia Sinica, Taipei, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Secondary mutation, T790M, conferring tyrosine kinase inhibitors (TKIs) resistance beyond oncogenic epidermal growth factor receptor (EGFR) mutations presents a challenging unmet need. Although TKI-resistant mechanisms are intensively investigated, the underlying responses of cancer cells adapting drug perturbation are largely unknown. To illuminate the molecular basis linking acquired mutation to TKI resistance, affinity purification coupled mass spectrometry was adopted to dissect EGFR interactome in TKI-sensitive and TKI-resistant non-small cell lung cancer cells. The analysis revealed TKI-resistant EGFR-mutant interactome allocated in diverse subcellular distribution and enriched in endocytic trafficking, in which gefitinib intervention activated autophagy-mediated EGFR degradation and thus autophagy inhibition elevated gefitinib susceptibility. Alternatively, gefitinib prompted TKI-sensitive EGFR translocating toward cell periphery through Rab7 ubiquitination which may favor efficacy to TKIs suppression. This study revealed that T790M mutation rewired EGFR interactome that guided EGFR to autophagy-mediated degradation to escape treatment, suggesting that combination therapy with TKI and autophagy inhibitor may overcome acquired resistance in non-small cell lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic AgentsHumansGefitinibErbB ReceptorsMutationProtein Kinase InhibitorsDrug Resistance, NeoplasmCell Line, Tumor

Stichwörter der Autor:innen

T790M mutationTKI-resistanceautophagyepidermal growth factor receptornon-small cell lung cancerprotein-protein interactiontyrosine kinase inhibitor

Substanzen

GefitinibErbB ReceptorsProtein Kinase InhibitorsAntineoplastic AgentsEGFR protein, human

Autor:innen und Institutionen

  • Genome and Systems Biology Degree Program, National Taiwan University, Taipei, Taiwan; Institute of Chemistry, Academia Sinica, Taipei, Taiwan.
  • Department of Microbiology, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Institute of Chemistry, Academia Sinica, Taipei, Taiwan.
  • Genome and Systems Biology Degree Program, National Taiwan University, Taipei, Taiwan; Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine, Taipei, Taiwan; Doctoral Degr…
  • Genome and Systems Biology Degree Program, National Taiwan University, Taipei, Taiwan; Institute of Chemistry, Academia Sinica, Taipei, Taiwan; Department of Chemistry, National Taiwan University, Taipei, Taiwan. Electr…

Förderung

  • Ministry of Science and Technology

Zitieren

APA

Wu, P. S., Lin, M. H., Hsiao, J. C., Lin, P. Y., Pan, S. H., & Chen, Y. J. (2023). EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer. Molecular & Cellular Proteomics, 22(9), 100624. https://doi.org/10.1016/j.mcpro.2023.100624

Vancouver

Wu PS, Lin MH, Hsiao JC, Lin PY, Pan SH, Chen YJ. EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer. Molecular & Cellular Proteomics. 2023;22(9):100624. doi:10.1016/j.mcpro.2023.100624

BibTeX
@article{Wu2023,
  author = {Wu, Pei-Shan and Lin, Miao-Hsia and Hsiao, Jye-Chian and Lin, Pei-Yi and Pan, Szu-Hua and Chen, Yu-Ju},
  title = {EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer},
  journal = {Molecular & Cellular Proteomics},
  year = {2023},
  volume = {22},
  number = {9},
  pages = {100624},
  doi = {10.1016/j.mcpro.2023.100624}
}
Kostenlos starten →